The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Trends in breast cancer mortality by stage at diagnosis among young women in the United States
Open accessAbstract
BACKGROUND: Assessing trends in breast cancer survival among young women who are largely unaffected by breast cancer screening will provide important information regarding improvements in the effectiveness of cancer care for breast cancer in the last few decades. METHODS: The cohort for this study consisted of women who were diagnosed with breast cancer between ages 20 and 39 years from the Surveillance, Epidemiology, and End Results program's 9‐registry areas from 1975 to 2015. Trends in the breast cancer incidence rate and survival were assessed among young women. RESULTS: Among women aged 20 to 39 years, breast cancer incidence increased from 24.6 per 100,000 in 1975 to 31.7 per 100,000 in 2015 (annual percent change, 0.5; 95% confidence interval [CI], 0.4‐0.6). Among women with breast cancer, 5‐year breast‐cancer‐specific survival increased significantly from 74.0% during 1975 to 1979 to 88.5% during 2010 to 2015 (hazard ratio for dying from breast cancer for 2010‐2015 vs 1975‐1979, 0.37; 95% CI, 0.32‐0.41). The increase in cancer‐specific survival reached a plateau in 2005; however, among young women with metastatic breast cancer, it continued to increase after 2005, from 45.6% during 2005 to 2009 to 56.5% during 2010 to 2015 (hazard ratio for dying from breast cancer for 2010‐2015 vs 2005‐2009, 0.74; 95% CI, 0.60‐0.92). Similar patterns also were observed for 5‐year overall survival and among women aged 20 to 29 years and those aged 30 to 39 years. CONCLUSIONS: There were substantial improvements in the effectiveness of breast cancer treatment on overall and cancer‐specific survival from 1975 to 2015. However, improvements appeared to have reached a plateau after 2005, except among young women with metastatic breast cancer, in whom survival continued to improve throughout the period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Non-Hispanic Black women also had the highest incidence for advanced staged disease, which likely contributes to their higher mortality rates.17,18,19”
From Breast Cancer Incidence Among US Women Aged 20 to 49 Years by Race, Stage, and Hormone Receptor Status (2024) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Human epithelial growth factor receptor 2 (HER2)directed therapies, such as the classic anti-HER2 antibody trastuzumab, have become available since late 1990s for the treatment of HER-2-positive, advanced breast cancer and have significantly reduced cancer deaths in these patients.(32,33) Improved breast cancer care F…”
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement
Siu, A. L., & on behalf of the U.S. Preventive Services Task Force (2016) · Annals of Internal Medicine · doi:10.7326/m15-2886 · Cited by 2,094
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Moderate Alcohol Consumption During Adult Life, Drinking Patterns, and Breast Cancer Risk
Chen, W. Y., Rosner, B., Hankinson, S. E., Colditz, G. A., & Willett, W. C. (2011) · JAMA · doi:10.1001/jama.2011.1590 · Cited by 509
Cited by
Xu, S., Murtagh, S., Han, Y., Wan, F., & Toriola, A. T. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.53331 · Cited by 178
Machine learning to guide the use of adjuvant therapies for breast cancer
Alaa, A. M., Gurdasani, D., Harris, A. L., Rashbass, J., & van der Schaar, M. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-021-00353-8 · Cited by 55
Metadata
- Authors
- Guo, F., Kuo, Y., Shih, Y. C. T., Giordano, S. H., & Berenson, A. B.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2018-09
- Volume
- 124
- Issue
- 17
- Pages
- 3500-3509
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2890101771
- Cited by
- 178
- References
- 6
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trends in breast cancer mortality by stage at diagnosis among young women in the United States. https://app.cochat.ai/papers/10.1002/cncr.31638
- The paper
- Guo, F., Kuo, Y., Shih, Y. C. T., Giordano, S. H., & Berenson, A. B. (2018). Trends in breast cancer mortality by stage at diagnosis among young women in the United States. Cancer. https://doi.org/10.1002/cncr.31638
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.